Journal of Medical Economics, Volume 16, Issue 9 (2013)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Journal of Medical Economics, Volume 16, Issue 9 (2013)

See all volumes and issues
Vol 27, 2024 Vol 26, 2023 Vol 25, 2022 Vol 24, 2021 Vol 23, 2020 Vol 22, 2019 Vol 21, 2018 Vol 20, 2017 Vol 19, 2016 Vol 18, 2015 Vol 17, 2014 Volume 16, 2013 Vol 15, 2012 Vol 14, 2011 Vol 13, 2010 Vol 12, 2009 Vol 11, 2008 Vol 10, 2007 Vol 9, 2006 Vol 8, 2005 Vol 7, 2004 Vol 6, 2003 Vol 5, 2002 Vol 4, 2001 Vol 3, 2000 Vol 2, 1999 Vol 1, 1998
Download citations Download PDFs Download issue

Original Articles

Article
Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic
Thomas R. Einarson, Roman Zilbershtein, Jana Skoupá, Šárka Veselá, Madhur Garg & Michiel E. H. Hemels
Pages: 1089-1095
Published online: 09 Jul 2013
AbstractforEconomic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic | Full Text | References | PDF (211.1 KB)
  • 861 Views
  • 10 CrossRef citations
  • 0Altmetric
Free Access
Article
Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland
Thomas R. Einarson, Hanna Pudas, Roman Zilbershtein, Rasmus Jensen, Colin Vicente, Charles Piwko & Michiel E. H. Hemels
Pages: 1096-1105
Published online: 31 Jul 2013
AbstractforCost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland | Full Text | References | PDF (323.4 KB)
  • 1232 Views
  • 12 CrossRef citations
  • 0Altmetric
Free Access
Article
Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial
I. M. Majer, H. Gelderblom, W. B. van den Hout, E. Gray & B. G. Verheggen
Pages: 1106-1119
Published online: 19 Jul 2013
AbstractforCost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial | Full Text | References | PDF (319.8 KB) | Supplemental
  • 750 Views
  • 11 CrossRef citations
  • 0Altmetric
Free Access
Article
Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis
Machaon Bonafede, George J. Joseph, Nicole Princic & David J. Harrison
Pages: 1120-1128
Published online: 18 Jul 2013
AbstractforAnnual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis | Full Text | References | PDF (127.9 KB)
  • 1257 Views
  • 19 CrossRef citations
  • 0Altmetric
Free Access
Article
Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients
Amit Sharma, Markus Ketteler, Thomas S. Marshall, Samina S. Khan & Glen T. Schumock
Pages: 1129-1136
Published online: 24 Jul 2013
AbstractforComparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients | Full Text | References | PDF (299.5 KB)
  • 762 Views
  • 4 CrossRef citations
  • 0Altmetric
Free Access
Article
Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies
Lin Xie, Wenhui Wei, Chunshen Pan & Onur Baser
Pages: 1137-1145
Published online: 02 Aug 2013
AbstractforReal-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies | Full Text | References | PDF (361.3 KB)
  • 867 Views
  • 9 CrossRef citations
  • 0Altmetric
Free Access
Article
Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment
Maureen J. Lage, Cathryn A. Carroll & Kathleen A. Fairman
Pages: 1146-1153
Published online: 08 Aug 2013
AbstractforUsing observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment | Full Text | References | PDF (159.6 KB)
  • 748 Views
  • 11 CrossRef citations
  • 0Altmetric
Free Access
Article
Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet
Vasily Belozeroff, Andrew Lee, Spring Tseng, Silvia Chiroli & Jonathan D. Campbell
Pages: 1154-1162
Published online: 06 Aug 2013
AbstractforCost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet | Full Text | References | PDF (160.8 KB)
  • 741 Views
  • 3 CrossRef citations
  • 0Altmetric
Free Access

Brief Report

Brief Report
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials
Steve Deitelzweig, Alpesh Amin, Yonghua Jing, Dinara Makenbaeva, Daniel Wiederkehr, Jay Lin & John Graham
Pages: 1163-1168
Published online: 08 Aug 2013
AbstractforMedical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials | Full Text | References | PDF (134.4 KB)
  • 983 Views
  • 14 CrossRef citations
  • 0Altmetric
Free Access

Explore articles

Explore the most recently published articles

The efficiency of TAVI in intermediate and low-risk Japanese patients.
Panagiotis Petrou
Editorial | Published online: 25 May 2024
Open Access
Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom
Mafalda Ramos et al.
Article | Published online: 17 May 2024
Open Access
Estimated impact and value of blood-based colorectal cancer screening at varied adherence compared with stool-based screening
John B. Kisiel et al.
Article | Published online: 13 May 2024
Open Access
Balancing innovation and ethics in AI governance for health technology assessment
João L. Carapinha et al.
Editorial | Published online: 13 May 2024
Open Access
View all latest articles